Teen Vulnerability to Irritability: Brain and Estrogen Changes (TeenVIBE)

University of North Carolina (UNC)

Status and phase: Begins enrollment this month; Phase 4

Conditions: Irritability; Depression - Major Depressive Disorder

Treatments: Drug: Kurvelo; Drug: Placebo COC

Study type: Interventional

Funder types: Other

Identifiers

NCT07544966

25-2243

Details and patient eligibility

About

Purpose: Risk of severe psychopathology increases dramatically during adolescence, especially for females. Changes in ovarian steroids across the menstrual cycle produce windows of vulnerability to mood disturbances, particularly during the abrupt withdrawal of estradiol (E2) and progesterone (P4) prior to menses onset. Irrefutable evidence links stress with affective symptoms, potentially mediated by E2-related modifications of frontolimbic connectivity and prefrontal gamma-aminobutyric acid (GABA) inhibitory signaling. The primary objective of this project is to empirically test the impact of E2 and P4 change on vulnerable brain networks associated with irritability and other depressive symptoms in female adolescents at risk of suicide.

Participants: The investigators will enroll 50 female adolescents ages 12-16 who are at risk of suicide (i.e., moderate depressive symptoms), and are eligible to receive oral contraceptives and undergo MRI imaging.

Procedure: Using a randomized, placebo-controlled, cross-over design, participants will be studied under two conditions: 8 weeks of E2 and P4 stabilization (continuous combined oral contraceptive (COC) to prevent perimenstrual withdrawal) and 8 weeks of placebo, with a 1-month washout after each condition. Each condition will include: 1) daily samples of E2 and P4 urinary metabolites, 2) daily symptom ratings(e.g., irritability, negative affect and suicidal thoughts and behaviors (STBs)), and 3) a neuroimaging session with MRI and magnetic resonance spectroscopy (MRS).

Enrollment: 50 estimated patients

Sex: Female

Ages: 12 to 16 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Assigned female sex at birth
• Between the ages of 12 and 16
• Be eligible to receive a low-dose oral contraceptive (COC)
• Post-menarche. Participants will be post-menarche to avoid potential OC-related effects on bone growth prior to menarche
• At risk of suicide. To be considered "at suicide risk" participants must meet the following-Mood and Feelings Questionnaire score of ≥ 27

Exclusion criteria

• Personal history of metabolic or autoimmune disease
• Epilepsy
• Endometriosis
• Cardiovascular, gastrointestinal, hepatic, renal, or pulmonary disease Diabetes mellitus with vascular disease
• Uncontrolled hypertension
• Liver tumors (benign or malignant) or liver disease
• Undiagnosed abnormal uterine bleeding
• Headaches with focal neurological symptoms or migraine with aura
• Known or suspected pregnancy
• Current or past deep vein thrombosis or pulmonary embolism
• Cerebrovascular disease Coronary artery disease
• Thrombogenic valvular or rhythm disease (e.g., subacute bacterial endocarditis with valvular disease, atrial fibrillation)
• Inherited or acquired hypercoagulopathies
• Current or history of breast cancer or other hormone-sensitive malignancy
• Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir
• Personal or first-degree relative with breast cancer or thromboembolic events

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

50 participants in 2 patient groups, including a placebo group

Kurvelo®, then Placebo COC

Active Comparator group

Description:

Participants will receive 8-weeks of continuous combined oral contraceptive (COC; Kurvelo®: 30mcg ethinyl estradiol (EE) and 0.15mg levonorgestrel (LNG), a synthetic estrogen and progestin, respectively). A 4-week washout period will then occur after which participants will receive 8-weeks of continuous placebo combined oral contraceptive (COC) pills.

Treatment:

Drug: Placebo COC

Drug: Kurvelo

Placebo COC, then Kurvelo®

Placebo Comparator group

Description:

Participants will receive 8-weeks of continuous placebo combined oral contraceptive (COC) pills. A 4-week washout period will then occur after which participants will receive 8-weeks of continuous combined oral contraceptive (COC; Kurvelo®: 30mcg ethinyl estradiol (EE) and 0.15mg levonorgestrel (LNG), a synthetic estrogen and progestin, respectively).

Treatment:

Drug: Placebo COC

Drug: Kurvelo